Scientists in Amsterdam just destroyed breast cancer tumors in 11 days without chemo

Any day where a new study shows a potential cure for cancer is a good day, and scientists in Europe may have found a breakthrough for breast cancer. The most common cancer in women, around 1 in 8 American women will develop it in their lifetime; the clinical trial may have found a way to rid us of it once and for all in the future.

Breast Cancer Breakthrough

Research presented by Professor Nigel Bundred at the European Breast Cancer Conference in Amsterdam revealed that they had tested the effectiveness of a pair of drugs known as Herceptin (a.k.a trastuzumab) and Lapatinib.

The two drugs are commonly used in breast cancer treatment already, but this is the first time they had been combined together and used before surgery and chemotherapy. They were able to eliminate some types of breast cancer in just 11 days.

Funded by Cancer Research UK, they aimed to use these drugs to combat a protein called HER2 (human epidermal growth factor receptor 2), which affects the growth and division of cancer cells. It’s also more likely to return than other cancer types.

What also makes this treatment so appealing is the fact that it may eliminate the need for chemotherapy and/or surgery in some cases.

Study Results

257 women with HER2 positive breast cancer were selected for the study.  In the first round, 130 women were assigned to one of three groups – some received Herceptin (trastuzumab), others received lapatinib. Both these groups were treated for 11 days after diagnosis and before surgery. A third group received no drug treatment before surgery (the control group). What they found was that of those on the combination of Herceptin and lapatinib, 7 of the 66 women had no cancer cells remaining within two weeks and an additional 11 women featured dramatically shrunken tumors.

Compared to the control group who were only given Herceptin, they were found to have 0% with no trace of cancer cells and only 3% showed a drop in tumor size. Clearly, the two drugs combined have a major effect on breast cancer cells as opposed to being used on their own.

The problem currently, however, is that Herceptin’s licensing makes it only available for use alongside chemotherapy and not alone. The results of this study may help to change that though.

Although there’s still a lot of work to be done, this is a major step in the fight against one of the world’s deadliest diseases. With medical advancements improving every year, it’s entirely possible this could happen sooner than we think!

Sources

McCarthy, A. (2016, March 11). ‘Unprecedented’ breast cancer trial results explained. Retrieved from http://scienceblog.cancerresearchuk.org/2016/03/11/unprecedented-breast-cancer-trial-results-explained/

Andrews, R. (2016, August 15). Remarkable Breast Cancer Trial Destroys Tumors In Just 11 Days. Retrieved from http://www.iflscience.com/health-and-medicine/remarkable-breast-cancer-trial-destroys-tumors-just-11-days/

Breastcancer.org. (n.d.). U.S. Breast Cancer Statistics. Retrieved from http://www.breastcancer.org/symptoms/understand_bc/statistics

The European Cancer Association. (2016, March 10). Combination of lapatinib and trastuzumab shrinks HER2 positive breast cancer significantly in 11 days after diagnosis. Retrieved from https://www.sciencedaily.com/releases/2016/03/160310125513.htm

MacMillan Cancer Support. (2015, September 1). HER2 positive breast cancer. Retrieved from http://www.macmillan.org.uk/cancerinformation/cancertypes/breast/aboutbreastcancer/typesandrelatedconditions/her2%20positive.aspx

Image Sources

https://pixabay.com/en/medic-hospital-laboratory-medical-563423/

http://www.shutterstock.com/pic-211307413/stock-photo-normal-chest-x-ray-of-woman.html?src=vqzUTO8k2o5xVewGxHO4gQ-1-71

The Hearty Soul

The Hearty Soul

The Hearty Soul is one of the world’s largest health information hubs. We connect regular people with cutting-edge research and the insights of medical professionals.
The Hearty Soul

Discover related articles

Read. Discover. Grow.